These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34312016)

  • 21. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.
    Kunacheewa C; Manasanch EE
    Expert Rev Hematol; 2021 Dec; 14(12):1059-1069. PubMed ID: 34550841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Smoldering multiple myeloma current treatment algorithms.
    Rajkumar SV; Kumar S; Lonial S; Mateos MV
    Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA; Rajkumar SV
    Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
    Korde N; Kristinsson SY; Landgren O
    Blood; 2011 May; 117(21):5573-81. PubMed ID: 21441462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.
    Agarwal A; Ghobrial IM
    Clin Cancer Res; 2013 Mar; 19(5):985-94. PubMed ID: 23224402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
    Visram A; Cook J; Warsame R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
    Landgren O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():478-87. PubMed ID: 24319222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smoldering multiple myeloma: present position and potential promises.
    Tageja N; Manasanch EE; Korde N; Kwok M; Mailankody S; Bhutani M; Roschewski M; Landgren O
    Eur J Haematol; 2014 Jan; 92(1):1-12. PubMed ID: 24112232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Smoldering multiple myeloma].
    Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
    Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Willrich MAV; Murray DL; Kyle RA
    Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
    Walker BA; Wardell CP; Melchor L; Brioli A; Johnson DC; Kaiser MF; Mirabella F; Lopez-Corral L; Humphray S; Murray L; Ross M; Bentley D; Gutiérrez NC; Garcia-Sanz R; San Miguel J; Davies FE; Gonzalez D; Morgan GJ
    Leukemia; 2014 Feb; 28(2):384-390. PubMed ID: 23817176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
    Maura F; Bolli N; Rustad EH; Hultcrantz M; Munshi N; Landgren O
    JAMA Oncol; 2020 Mar; 6(3):425-432. PubMed ID: 31830214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smoldering multiple myeloma.
    Rajkumar SV; Landgren O; Mateos MV
    Blood; 2015 May; 125(20):3069-75. PubMed ID: 25838344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
    Bladé J; Rosiñol L
    Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smoldering multiple myeloma: biology, clinical manifestations and management.
    Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
    Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.